Dr. Gabor Maté, recognised physician and bestselling author, joins Numinus as Member of the Clinical Advisory Council

Maté will collaborate with the Numinus team in an advisory capacity and facilitate connections within the mental health community

VANCOUVER (May 26th, 2020) – Numinus Wellness Inc. (“Numinus”; TSX-V: NUMI) is pleased to announce the appointment of Dr. Gabor Maté, MD, CM, as a Member of the Numinus Clinical Advisory Council. Through over 30 years' work in family practice, palliative care and addiction medicine, Dr. Maté has pioneered therapies and innovative, trauma-based approaches to mental health. His advocacy for mental health research and awareness have earned him international recognition from the healthcare community.

“We at Numinus are extremely honoured and excited to have someone with Gabor’s pedigree and on-the-ground experience,” says Numinus CEO Payton Nyquvest. “Gabor offers exceptional insight on the mental health landscape and its future, which greatly complements our goals and mission at Numinus.”

As a Member of the Clinical Advisory Council, Dr. Maté will be a vital resource in helping Numinus develop treatments and drive policy changes within the healthcare industry. Additionally, Dr. Maté will also use his network to enhance Numinus's collaboration with other leading researchers and groups working in mental illness, addiction and trauma treatment.

“Gabor is a well-respected clinician with a wealth of knowledge on the links between trauma and mental health, as well as ways to promote healing,” says Dr. Evan Wood, Chief Medical Officer of Numinus. “He has been on the forefront of innovative mental health strategies for many years and I look forward to collaborating with him to advance the Numinus model.”

Dr. Maté is internationally recognised for his expertise in addiction, trauma, childhood development, and the link between stress and illness. Beyond his work as a medical practitioner, he is a sought-after speaker and bestselling author with reprints in over 25 languages. His book on addiction received the Hubert Evans Prize for literary non-fiction. For his groundbreaking medical work and writing, he has been awarded the Order of Canada, Canada’s highest civilian distinction, and the Civic Merit Award from his hometown of Vancouver, B.C.

As part of his effort to broaden public awareness of mental illness and contribute to the local community, Dr. Maté spent over a decade working in Vancouver's Downtown Eastside caring for patients facing severe addiction and mental health challenges. Dr. Maté continues to push boundaries and identify new pathways for healing and advancement in mental health.

- 30 -

Contact:

Investor Inquiries:
invest@numinus.ca

Media Inquiries:
Emily Edwards, NATIONAL
eedwards@national.ca
604-842-6490

General Inquiries:
hello@numinus.ca

1-833-NUM-INUS (1-833-686-4687)

Pour investir et obtenir des renseignements généraux en français:
Remy Scalabrini, Maricom
investir@numinus.ca
888-585-6274

About Numinus

Numinus is a Vancouver-based health care company helping to support the universal desire to heal and be well. Through its wholly-owned subsidiary Salvation Botanicals, Numinus has a Health Canada cannabis testing licence that allows the company to test and analyze cannabis products from licensed producers. In addition, it is a late-stage applicant to receive a Health Canada standard processing licence to produce cannabis products. Numinus, through the same subsidiary, also has a dealer’s licence which allows the company to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline. It is seeking to expand the licence to include activities such as import/export, testing and R&D. The expanded licence will allow Numinus to support the growing number of studies on the potential benefits of psychedelic therapies through research projects, product development, and the supply and distribution of these substances. Numinus Wellness is dedicated to therapies that enhance and supplement existing options for people wanting lasting physical, mental and emotional health — with psychedelic treatments at its core when approved for therapeutic and research use. Psychedelics will be part of this offering but will only be available for treatment once approved by regulators and governing bodies — a process Numinus is helping to support. For more information, visit www.numinus.ca.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to operate and expand the Company’s facilities; engaging in activities which currently are illegal under Canadian federal law and the uncertainty of existing protection from Canadian federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, including closing of the financings contemplated herein; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.